Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 2/20 | 0.49 |
| ▸ | CTSB | P07858 | 2/20 | 0.49 |
| ▸ | CTSS | P25774 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.47 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.41 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.41 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 2/20 | 0.40 |
| ▸ | TACR1 | P25103 | 1/20 | 0.40 |
| ▸ | DDB1 | Q16531 | 1/20 | 0.39 |
| ▸ | CRBN | Q96SW2 | 1/20 | 0.39 |
| ▸ | CTSK | P43235 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25094700 | 0.96 | ALDH1A1 (0.49) | CTSLCTSBCTSSALDH1A1MAPK1 | |
| SCHEMBL27360347 | 0.81 | CTSL (0.59) | CTSLCTSBCTSSALDH1A1KMT2A | |
| SCHEMBL394093 | 0.77 | ALDH1A1 (0.50) | CTSLCTSBCTSSALDH1A1MAPK1 | |
| SCHEMBL7509351 | 0.77 | ALDH1A1 (0.53) | CTSLCTSBCTSSALDH1A1MAPK1 | |
| SCHEMBL1912656 | 0.77 | ALDH1A1 (0.53) | CTSLCTSBCTSSALDH1A1MAPK1 | |
| SCHEMBL25991 | 0.76 | ALDH1A1 (0.43) | CTSLCTSBCTSSALDH1A1MAPK1 | |
| SCHEMBL27534954 | 0.76 | ALDH1A1 (0.49) | CTSLCTSBCTSSALDH1A1MAPK1 | |
| SCHEMBL14148977 | 0.76 | ALDH1A1 (0.50) | CTSLCTSBCTSSALDH1A1MAPK1 | |
| SCHEMBL10408165 | 0.76 | ALDH1A1 (0.45) | CTSLCTSBCTSSALDH1A1MAPK1 | |
| Hydrochloric Acid SCHEMBL3699844 | 0.75 | ALDH1A1 (0.51) | CTSLCTSBCTSSALDH1A1MAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0432504-B1 | Process for preparing 1-(aminomethyl)cyclohexane acetic acid | LONZA AG (CH) | 1994-06-08 | — | — | EP | claimed |
| US-5149870-A | Process for the production of 1-(aminomethyl)cyclohexane acetic acid | LONZA LTD. (CH) | 1992-09-22 | — | — | US | claimed |
| US-5136091-A | Alcoholysis, hydrolysis, transesterification, and hydrogenatio hydrogenation; acid & basic catalysts; anticonvulsants | LONZA LTD. (CH) | 1992-08-04 | — | — | US | claimed |
| US-5095148-A | PROCESS FOR THE PRODUCTION OF 1-(AMINOMETHYL)CYCLOHEXANE ACETIC ACID | LONZA LTD. (CH) | 1992-03-10 | — | — | US | claimed |
| JP-3176459-A | — | — | None | — | — | JP | disclosed |
| WO-2010023694-A2 | CRYSTALLINE FORMS OF GABAPENTIN AND PROCESS THEREOF | HIKAL LTD (IN) | 2010-03-04 | — | — | WO | disclosed |
| EP-1603863-B1 | PROCESS FOR THE PREPARATION OF AMINO METHYL CYCLO ALKANE ACETIC ACIDS | HIKAL LTD (IN) | 2010-01-13 | — | — | EP | disclosed |
| US-7635717-B2 | Process for the preparation of amino methyl cyclo alkane acetic acids | HIKAL LIMITED (IN) | 2009-12-22 | — | — | US | disclosed |
| US-20060149099-A1 | Process for the preparation of amino methyl cyclo alkane acetic acids | HIKAL LIMITED | 2006-07-06 | — | — | US | disclosed |
| EP-1603863-A1 | PROCESS FOR THE PREPARATION OF AMINO METHYL CYCLO ALKANE ACETIC ACIDS | Hikal Ltd. (IN) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004046085-A1 | PROCESS FOR THE PREPARATION OF AMINO METHYL CYCLO ALKANE ACETIC ACIDS | HIKAL LTD. (IN) | 2004-06-03 | — | — | WO | disclosed |
| US-5149870-A | Process for the production of 1-(aminomethyl)cyclohexane acetic acid | LONZA LTD. (CH) | 1992-09-22 | — | — | US | disclosed |
| US-5136091-A | Alcoholysis, hydrolysis, transesterification, and hydrogenatio hydrogenation; acid & basic catalysts; anticonvulsants | LONZA LTD. (CH) | 1992-08-04 | — | — | US | disclosed |
| US-5130455-A | Anticonvulsants | LONZA LTD. (CH) | 1992-07-14 | — | — | US | disclosed |
| US-5095148-A | PROCESS FOR THE PRODUCTION OF 1-(AMINOMETHYL)CYCLOHEXANE ACETIC ACID | LONZA LTD. (CH) | 1992-03-10 | — | — | US | disclosed |
| JP-H03176459-A | PROCESS FOR THE PRODUCTION OF 1-(AMINOMETHYL)CYCLOHEXANE ACETIC ACID | LONZA AG | 1991-07-31 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060149099-A1 | Process for the preparation of amino methyl cyclo alkane acetic acids | GABRA1, GABRA6, ACMSD | CTSL 3541/4885CTSB 3134/4885CTSS 2903/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.